国内精品一战二战三战,日本亚州视频在线八A,999久久久国产精品,精品人妻无码AV波多野结衣

玉研儀器公司——專(zhuān)注于動(dòng)物實(shí)驗(yàn)設(shè)備的技術(shù)產(chǎn)品和服務(wù)

取消

清空記錄

歷史記錄

清空記錄

歷史記錄

清空記錄

歷史記錄

上海玉研科學(xué)儀器有限公司
產(chǎn)品
聯(lián)系
QQ: 2881513766

小動(dòng)物皮下**測(cè)量?jī)x

分享到微信

×
動(dòng)物**測(cè)量?jī)x,非常適合對(duì)大鼠小鼠等動(dòng)物體內(nèi)的**進(jìn)行快速測(cè)量、分析,精確測(cè)量動(dòng)物**并對(duì)**信息存檔與追蹤!
公眾號(hào)
產(chǎn)品詳情

動(dòng)物**測(cè)量?jī)x,非常適合對(duì)大鼠小鼠等動(dòng)物的皮下**進(jìn)行快速測(cè)量、分析,精確測(cè)量動(dòng)物**并對(duì)**信息存檔與跟蹤。



主要技術(shù)參數(shù): 

· 測(cè)量范圍:0-25mm**尺寸:20*20*20mm
· 3D測(cè)量精確度:<0.3mm
· 圖像捕捉時(shí)間:0.1s
· 接口:USB 2.0
· 相機(jī):1600*1200 像素(2MP)
· 工作距離:50mm


動(dòng)物**測(cè)量分析儀的主要特點(diǎn): 
· 手持式成像裝置,實(shí)現(xiàn)立體成像;
· 適合測(cè)量不同尺寸的**;
· 方便使用:觸屏式電腦,操作方便;
· 內(nèi)置軟件,自動(dòng)計(jì)算**尺寸,跟蹤整個(gè)實(shí)驗(yàn)進(jìn)展。 
  

· 快速,高效,保證了高通量和可靠測(cè)量;
· 全自動(dòng)測(cè)量跟蹤系統(tǒng);
· 實(shí)時(shí)數(shù)據(jù)分析與處理。 


  
  


部分用戶 

Hunter College, CUNY

Vanderbilt University Medical Center

Hainan Medical University

Howard Hughes Medical Institute

Memorial Sloan Kettering Cancer Center

Cancer Center Amsterdam

GlaxoSmithKline

Imec

K.U.Leuven

Neuro-Electronics Research Flanders

Pepric

PharmaVize

reMYND

University Ghent

SEPS Pharma

Vlaams Instituut voor Biotechnologie

University Antwerp

ThromboGenics

Janssen Pharmaceutica

City University of Hong Kong


參考文獻(xiàn):


1.Adams EJ, Karthaus WR, Hoover E, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408-412. doi:10.1038/s41586-019-1318-9.
2.Zhang Z, Zhou C, Li X, et al. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell. 2020;37(4):584-598.e11. doi:10.1016/j.ccell.2020.03.001.
3.Santich BH, Park JA, Tran H, et al. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Sci Transl Med. 2020;12(534):eaax1315. doi:10.1126/scitranslmed.aax1315.
4.Park JA, Xu H, Cheung, I, et al. Abstract B38: Tetravalent bispecific antibodies specific for HER2 and disialoganglioside GD2 to engage polyclonal T cells for osteosarcoma therapy. Cancer Res. 2018;78(19),B38.doi:10.1158/1538-7445.PEDCA17-B38.
5.Wu CF, Wu CY, Lin CF, et al. The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. Biomed Pharmacother. 2022;151:113128. doi:10.1016/j.biopha.2022.113128.
6.Wang L, Hoseini SS, Xu H, et al. Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency. Cancer Immunol Res. 2019;7(12):2013-2024. doi:10.1158/2326-6066.CIR-19-0121.
7.Grochowska A, Statkiewicz M, Kulecka M, et al. Evidence supporting the oncogenic role of BAZ1B in colorectal cancer. Am J Cancer Res. 2022;12(10):4751-4763. 
8.Hoseini SS, Vadlamudi M, Espinosa-Cotton M, et al. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. J Immunother Cancer. 2021;9(5):e002509. doi:10.1136/jitc-2021-002509.
9.Beguin E, Gray MD, Logan KA, et al. Magnetic microbubble mediated chemo-sonodynamic therapy using a combined magnetic-acoustic device. J Control Release. 2020;317:23-33. doi:10.1016/j.jconrel.2019.11.013.
10.Mao N, Gao D, Hu W, et al. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes. Mol Cancer Ther. 2019;18(9):1577-1586. doi:10.1158/1535-7163.MCT-18-1386.
11.Wu Z, Guo HF, Xu H, et al. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers. Mol Cancer Ther. 2018;17(10):2164-2175. doi:10.1158/1535-7163.MCT-18-0026.
12.Poty S, Mandleywala K, O'Neill E, et al. 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics. 2020;10(13):5802-5814. doi:10.7150/thno.44772.
13.Hoseini SS, Guo H, Wu Z, et al. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Adv. 2018;2(11):1250-1258. doi:10.1182/bloodadvances.2017014373.
14.Zhang Z, Karthaus WR, Lee YS, et al. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020;38(2):279-296.e9. doi:10.1016/j.ccell.2020.06.005.
15.Poty S, Carter LM, Mandleywala K, et al. Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2019;25(2):868-880. doi:10.1158/1078-0432.CCR-18-1650.


小動(dòng)物皮下**測(cè)量?jī)x
小動(dòng)物皮下**測(cè)量?jī)x

小動(dòng)物皮下**測(cè)量?jī)x

分享到微信

×
動(dòng)物**測(cè)量?jī)x,非常適合對(duì)大鼠小鼠等動(dòng)物體內(nèi)的**進(jìn)行快速測(cè)量、分析,精確測(cè)量動(dòng)物**并對(duì)**信息存檔與追蹤!
021-35183767
公眾號(hào)
產(chǎn)品詳情

動(dòng)物**測(cè)量?jī)x,非常適合對(duì)大鼠小鼠等動(dòng)物的皮下**進(jìn)行快速測(cè)量、分析,精確測(cè)量動(dòng)物**并對(duì)**信息存檔與跟蹤。



主要技術(shù)參數(shù): 

· 測(cè)量范圍:0-25mm**尺寸:20*20*20mm
· 3D測(cè)量精確度:<0.3mm
· 圖像捕捉時(shí)間:0.1s
· 接口:USB 2.0
· 相機(jī):1600*1200 像素(2MP)
· 工作距離:50mm


動(dòng)物**測(cè)量分析儀的主要特點(diǎn): 
· 手持式成像裝置,實(shí)現(xiàn)立體成像;
· 適合測(cè)量不同尺寸的**;
· 方便使用:觸屏式電腦,操作方便;
· 內(nèi)置軟件,自動(dòng)計(jì)算**尺寸,跟蹤整個(gè)實(shí)驗(yàn)進(jìn)展。 
  

· 快速,高效,保證了高通量和可靠測(cè)量;
· 全自動(dòng)測(cè)量跟蹤系統(tǒng);
· 實(shí)時(shí)數(shù)據(jù)分析與處理。 


  
  


部分用戶 

Hunter College, CUNY

Vanderbilt University Medical Center

Hainan Medical University

Howard Hughes Medical Institute

Memorial Sloan Kettering Cancer Center

Cancer Center Amsterdam

GlaxoSmithKline

Imec

K.U.Leuven

Neuro-Electronics Research Flanders

Pepric

PharmaVize

reMYND

University Ghent

SEPS Pharma

Vlaams Instituut voor Biotechnologie

University Antwerp

ThromboGenics

Janssen Pharmaceutica

City University of Hong Kong


參考文獻(xiàn):


1.Adams EJ, Karthaus WR, Hoover E, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408-412. doi:10.1038/s41586-019-1318-9.
2.Zhang Z, Zhou C, Li X, et al. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell. 2020;37(4):584-598.e11. doi:10.1016/j.ccell.2020.03.001.
3.Santich BH, Park JA, Tran H, et al. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Sci Transl Med. 2020;12(534):eaax1315. doi:10.1126/scitranslmed.aax1315.
4.Park JA, Xu H, Cheung, I, et al. Abstract B38: Tetravalent bispecific antibodies specific for HER2 and disialoganglioside GD2 to engage polyclonal T cells for osteosarcoma therapy. Cancer Res. 2018;78(19),B38.doi:10.1158/1538-7445.PEDCA17-B38.
5.Wu CF, Wu CY, Lin CF, et al. The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. Biomed Pharmacother. 2022;151:113128. doi:10.1016/j.biopha.2022.113128.
6.Wang L, Hoseini SS, Xu H, et al. Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency. Cancer Immunol Res. 2019;7(12):2013-2024. doi:10.1158/2326-6066.CIR-19-0121.
7.Grochowska A, Statkiewicz M, Kulecka M, et al. Evidence supporting the oncogenic role of BAZ1B in colorectal cancer. Am J Cancer Res. 2022;12(10):4751-4763. 
8.Hoseini SS, Vadlamudi M, Espinosa-Cotton M, et al. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. J Immunother Cancer. 2021;9(5):e002509. doi:10.1136/jitc-2021-002509.
9.Beguin E, Gray MD, Logan KA, et al. Magnetic microbubble mediated chemo-sonodynamic therapy using a combined magnetic-acoustic device. J Control Release. 2020;317:23-33. doi:10.1016/j.jconrel.2019.11.013.
10.Mao N, Gao D, Hu W, et al. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes. Mol Cancer Ther. 2019;18(9):1577-1586. doi:10.1158/1535-7163.MCT-18-1386.
11.Wu Z, Guo HF, Xu H, et al. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers. Mol Cancer Ther. 2018;17(10):2164-2175. doi:10.1158/1535-7163.MCT-18-0026.
12.Poty S, Mandleywala K, O'Neill E, et al. 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics. 2020;10(13):5802-5814. doi:10.7150/thno.44772.
13.Hoseini SS, Guo H, Wu Z, et al. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Adv. 2018;2(11):1250-1258. doi:10.1182/bloodadvances.2017014373.
14.Zhang Z, Karthaus WR, Lee YS, et al. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020;38(2):279-296.e9. doi:10.1016/j.ccell.2020.06.005.
15.Poty S, Carter LM, Mandleywala K, et al. Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2019;25(2):868-880. doi:10.1158/1078-0432.CCR-18-1650.


更多推薦
選擇區(qū)號(hào)
在线天堂中文www官网| 性大片免费视频观看| 久久久久久亚洲精品| av网站的免费观看| 苍井空高潮喷水| 中文字幕无码毛片免费看| 精品丝袜人妻久久久久久| 色翁荡息又大又硬又粗又视频软件 | 日韩AV无码中文字幕 | 精品国精品国产自在久国产 | 欧美成人WWW在线观看| 国产一区二区三区不卡在线看 | 久久婷婷综合缴情亚洲狠狠| 天天爽夜夜爽人人爽| 又黄又爽又色视频| 久久久久久国产精品无码超碰| avtt香蕉久久| 精品久久久无码人妻字幂 | 亚洲日韩国产二区无码| 俺来也俺去啦久久综合网| 99久久亚洲综合精品成人网| 免费无码A片一区二三区| 国产成人精品午夜二三区波多野| 久久精品人人槡人妻人人玩AV| 精品乱码久久久久久久| 国产激情精品一区二区三区| 国产亚洲精品美女久久久M| 亚洲第一av网站| 无码国产激情在线观看| 国产欲女高潮正在播放| 边摸边吃奶边做爽免费视频99| 少妇精品揄拍高潮少妇| 性猛交ⅹxxx富婆视频| 欧美精品视频大全在线观看| 久久亚洲中文字幕精品有坂深雪| 少妇扒开毛茸茸的B自慰 | 激情内射亚洲一区二区三区爱妻 | 欧美日韩亚洲中文字幕一区二区三区| 日本一区二区三区专线| 久久99久久99精品中文字幕| 精品日产一卡2卡三卡4卡自拍|